A Life Sciences Advisory Board has been launched by Atropos Health, a company that translates data into personalized real-world insights across healthcare.
Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 million in new funding from the U.S. Department of Defense, to develop technologies for needle-free vaccines.
PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), has received approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.
Sofia Baig is the president of clinical solutions at Precision for Medicine. As a strategic industry leader, she is adept driving organizational change and delivering top- and bottom-line growth.
Outsourcing Pharma is delighted to invite you to join our not-to-be-missed webinar on one of the most important areas of the industry – patient centricity – and its solutions.
Sanofi is planning to expand the market for its best-selling anti-inflammatory drug Dupixent, used to treat COPD, also known as ‘smokers lung’, after a successful second phase 3 trial.
It is five years this month since a ground-breaking change in UK healthcare history happened – with doctors being able to prescribe cannabis-based medicines for the first time.
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are common in solid tumors, including lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
At the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Arrowhead Pharmaceuticals unveiled the phase 2 clinical data for plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3).
The FDA has delayed its decision on whether to approve Bristol Myers Squibb and 2seventy bio’s CAR-T cell therapy, as it plans to seek further advice from experts.
OSP was delighted to talk to Vetter’s Carsten Press, a senior leader of the global sales organization, and business development among many operational functions.
A partnership combining an integrated drug creation platform with a company specializing in dermatological expertise will deliver life-changing medicines to patients.
Oxford-based SynaptixBio, whose aim is to find a treatment for TUBB4A-related leukodystrophies, has been awarded a £490,000 BioMedical Catalyst grant from Innovate UK to tackle less common variants of the disease.
At last month’s CPHI Barcelona, Sirio launched its new ready-to-market menopause and eye health softgels in a bid to collaborate with over the counter (OTC) brands and large pharmacy chains looking to advance to market faster.
Verici Dx, a company developing advanced clinical diagnostics for organ transplant, has entered into a global licensing partnership with healthcare giant Thermo Fisher to develop an assay for pre-transplant kidney testing.
Valneva recently received the greenlight for IXCHIQ by the US Food and Drug Administration (FDA), marking the approval of the world’s first chikungunya vaccine.
The Pistoia Alliance is a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D. It has just announced its four new strategic priorities made up of global pharma and tech representatives to deliver new project...
Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.
Legend Biotech, a biotechnology company developing novel therapies to treat life-threatening diseases, has entered into an exclusive, global license agreement with Novartis Pharma.
Glox Therapeutics, a company developing precision antibiotic therapies based on naturally occurring bacteriocins, has raised £4.3m in seed funding to develop targeted therapeutics against antibiotic-resistant Gram-negative bacteria.
Ever since injections promising to help people lose weight hit the shelves, interest around the world has been phenomenal. So high was demand, companies were finding it difficult to keep up with the demand.
IO Biotech, a clinical-stage biopharma company developing therapeutic cancer vaccines, has completed enrollment in its phase 3 trial for IO102-IO103, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced melanoma....
Angle, a liquid biopsy company with circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, has launched its Portrait PD-L1 test for the evaluation of PD-L1 protein expression on CTCs.
Medix Biochemicals has acquired ViroStat in an effort to provide its customers with infectious disease antibodies and antigens for their IVD immunoassay test development.
Johnson & Johnson’s Janssen Supply Group is to be the first tenant in Fujifilm Diosynth Biotechnologies’ $2 billion cell culture manufacturing facility, which is planned to open in Holly Springs, North Carolina, in 2025.
The Chinese contract research, development and manufacturing organization (CRDMO) WuXi XDC has launched a bid to raise up to HK$3.7 billion (US$470.3 million) in an initial public offering (IPO) on the Hong Kong Stock Exchange.
The proof-of-concept trial, dubbed IRIS-RA, is the first to investigate a treatment for rheumatoid arthritis that blocks a protein called neonatal Fc receptor (FcRn).
The antibody drug nipocalimab, developed by the Janssen Pharmaceutical...
The Belgian biotech company Galapagos will work with Landmark Bio to deliver CAR-T cell therapies to patients more quickly than with traditional manufacturing methods.
The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech company’s bispecific antibody cancer drug PM8002 in all territories except for Greater China.
The Australian biotech GPN Vaccines has expanded a partnership with compatriot contract development and manufacturing organization (CDMO) BioCina to scale up the manufacture of its lead candidate vaccine against pneumococcal diseases such as pneumonia,...
Vice president and global head of bioanalytical and central lab services, Lan Li has always found doctors fascinating. Their ability to save lives and give second chances set her on her career path, but it was recognizing there were still so many unmet...
The big pharma company Bristol Myers Squibb (BMS) committed up to $180 million for a phase 1-ready antibody-drug conjugate (ADC) for the treatment of blood cancer from the U.S.-South Korean biotech company Orum Therapeutics.
As it extends its cash runway, the cell therapy developer Atara Biotherapeutics has expanded a partnership with Pierre Fabre Laboratories to commercialize the off-the-shelf T-cell therapy tabelecleucel (tab-cel) for a rare form of blood cancer.
The UK has unveiled £34.5 million ($42.8 million) in funding for four hubs dedicated to the development of vaccines for diseases with epidemic potential in low- and middle-income countries (LMICs).
The Swiss biotech company Memo Therapeutics (MTx) has bagged CHF 25 million ($27.7 million) in a Series C round to finish the phase 2 development of its lead antibody treatment.
The US investment firm Bioluminescence Ventures (BLV) has emerged from stealth with $477 million to finance biotech companies developing first-in-class or best-in-class disease treatments.
The Indian contract research development and manufacturing organization (CRDMO) Aragen Life Sciences will invest $30 million in building a 160,000 square-meter biologics manufacturing facility in Bangalore.
Sarepta Therapeutics has hit a setback as its approved gene therapy Elevidys missed the primary goal of a phase 3 trial in children aged 4 through 7 years with the inherited disease Duchenne muscular dystrophy (DMD).
The French biotech company Vect-Horus has licensed its technology to the Danish big pharma Novo Nordisk to deliver drug cargoes to undisclosed disease targets in three programs.
The London and New York-based gene therapy player MeiraGTx Holdings has received a $30 million investment from Sanofi in addition to potential strategic deals with the big pharma company down the road.